Skip to main content
SpringerLink
Log in

Selecting an Antidepressant for Use in a Patient with Epilepsy

Safety Considerations

  • Review Article
  • Drug Safety Concept
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Depression is a common and disabling condition and is especially disabling for patients who also have epilepsy. Antidepressants, particularly the tricyclic antidepressants are well known to be associated with seizure activity, but this is a very neglected area of research. Most of the data on the proconvulsive effects of antidepressants come from either work in animal models or from research into the effects of antidepressants in overdose. Both of these situations may tell us little about the behaviour of antidepressants in patients with epilepsy. The selective serotonin [5-hydroxytryptamine; 5-HT] reuptake inhibitors have a low seizure propensity, are well tolerated in overdose and have a favourable adverse effect profile, making them suitable as first line treatments for depression in patients with epilepsy. Other antidepressants, e.g. trazodone, moclobemide, mirtazepine, are also likely to have minimal proconvulsive effects, but adverse effects, interactions with other drugs, especially anticonvulsants, or the lack of clinical data may make their use less attractive. Although this review has focused on these clinically important issues it is clear that considerably more research needs to be undertaken on the seizure propensity and clinical efficacy of antidepressants in patients with epilepsy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gawel MJ. Some issues in clinical neurology. In: Weller M, Eysenck M, editors. The scientific basis of psychiatry. 2nd ed. London: W.B. Saunders, 1992: 213–39

    Google Scholar 

  2. Trimble MR, Howard AR, Schmitz B. Neuropsychiatric aspects of epilepsy. In: Fogel BS, Schiffer RB, Rao SM, editors. Neuropsychiatry. Baltimore: Williams and Wilkins, 1996: 771–803

    Google Scholar 

  3. International Epilepsy Association. Commission on classification and terminology of the International League Against Epilepsy. Epilepsia 1981; 22: 489–501

    Article  Google Scholar 

  4. Currie S, Heathfield KWG, Henson RA, et al. Clinical course and prognosis of temporal lobe epilepsy. Brain 1971; 94: 173–90

    Article  PubMed  CAS  Google Scholar 

  5. Edeh J, Toone BK. Antiepileptic therapy, folate deficiency and psychiatric morbidity; a general practice survey. Epilepsia 1985; 26: 434–40

    Article  PubMed  CAS  Google Scholar 

  6. Gerner RH. Treatment of acute mania. Psych Clin North Am 1993; 16: 443–60

    CAS  Google Scholar 

  7. International Classification of Diseases, 10th edition. Geneva: World Health Organization, 1992: 110–31

  8. Barraclough B. Suicide and epilepsy. In: Reynolds EH, Trimble MR, editors. Epilepsy and psychiatry. Edinburgh: Churchill Livingstone, 1981: 72–6

    Google Scholar 

  9. Grahame-Smith DG. How does electroconvulsive therapy work? In: Malkin JC, Brandon S, editors. Current approaches: ECT. Dorchester: Henry Ling Ltd., 1988: 43–8

    Google Scholar 

  10. Green AR. Changes in gamma aminobutyric acid biochemistry and seizure threshold. In: Malitz S, Sackeim HA, editors. Electroconvulsive therapy: clinical and basic research issues. New York: New York Academy of Sciences, 1986: 105–17

    Google Scholar 

  11. Markowitz JC, Brown RP. Seizures with neuroleptics and antidepressants. Gen Hosp Psychiatry 1987; 9(2): 135–41

    Article  PubMed  CAS  Google Scholar 

  12. Rosenstein DL, Nelson C, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54(8): 289–99

    PubMed  CAS  Google Scholar 

  13. Minabe Y, Emori K, Kurachi M. Effects of chronic lithium treatment limbic seizure generation in the cat. Psychopharmacology 1988; 96(3): 391–4

    Article  PubMed  CAS  Google Scholar 

  14. Bazire S. Psychotropic drug directory. Salisbury: Quay Books, 1997

    Google Scholar 

  15. Perry PJ, Alexander B, Liskow BI. Psychotropic drug handbook. 7th ed. Washington, DC: American Psychiatric Press, 1997: 453–501

    Google Scholar 

  16. Shannon M, Merola J, Lovejoy Jr FH. Hypotension in severe tricyclic antidepressant overdose. Am J Emerg Med 1988; 6(5): 435–42

    Article  Google Scholar 

  17. Wroblewski BA, McColgan K, Smith K, et al. The incidence of seizures during tricyclic antidepressant drug treatment in the brain-injured population. J Clin Psychopharmacol 1990; 10(2): 124–8

    Article  PubMed  CAS  Google Scholar 

  18. Rasmussen JGC, Johnson AM. Incidence of seizures during treatment with antidepressants, including the new selective serotonin re-uptake inhibitor, paroxetine. Proceedings of the 5th World Congress of Biological Psychiatry; 1991 Jun 9–14: Florence: 40–1

    Google Scholar 

  19. Dessain EC, Schatberg AF, Woods BT. Maprotiline treatment in depression: a perspective on seizures. Arch Gen Psychiatry 1986; 43: 86–90

    Article  PubMed  CAS  Google Scholar 

  20. Ojemann LM, Friel PN, Trejo WL et al. Effect of doxepin on seizure frequency in depressed epileptic patients. Neurology 1983; 33: 646–8

    Article  PubMed  CAS  Google Scholar 

  21. Rickels K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990; 51(12) Suppl. B: 9–12

    PubMed  Google Scholar 

  22. Harris CR, Gualtieri J, Stark G. Fatal bupropion overdose. J Toxicol Clin Toxicol 1997; 35(3): 321–4

    Article  PubMed  CAS  Google Scholar 

  23. Krijzer F, Snelder M, Bradford D. Comparison of the (pro)convulsive properties of fluvoxamine and clovoxamine with eight other antidepressants in an animal model. Neuropsychobiology 1984; 12: 249–54

    Article  PubMed  CAS  Google Scholar 

  24. Foulke GE, Albertson TE. QRS interval in tricyclic antidepressant overdosage: inaccuracy as a toxicity indicator in emergency settings. Ann Emerg Med 1987; 16(2): 160–3

    Article  PubMed  CAS  Google Scholar 

  25. Warter JM, Tranchant C, Marescaux C, et al. Immediate effects of 14 non-MAOI antidepressants in rats with spontaneous petit mal—like seizures. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 261–70

    Article  PubMed  CAS  Google Scholar 

  26. James LP, Kearns GL. Cyclic antidepressant toxicity in children and adolescents. J Clin Pharmacol 1995; 35(4): 343–50

    PubMed  CAS  Google Scholar 

  27. Liebelt EL, Francis PD, Woolf AD. EEG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med 1995; 26(2): 195–201

    Article  PubMed  CAS  Google Scholar 

  28. Taboulet P, Michard F, Muszynski J. Cardiovascular repercussions of seizures during cyclic antidepressant poisoning. J Toxicol 1995; 33(3): 205–11

    CAS  Google Scholar 

  29. Ellison DW, Pentel PR. Clinical features and consequences of seizures due to cyclic antidepressant overdose. Am J Emerg Med 1989; 7(1): 5–10

    Article  PubMed  CAS  Google Scholar 

  30. Buckley NA, Dawson AH, Whyte IM, et al. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet 1994; 343(8890): 159–62

    Article  PubMed  CAS  Google Scholar 

  31. Feighner JP, Boyer WF. Selective serotonin re-uptake inhibitors: the clinical use of Citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline. Vol. 1. Chichester: John Wiley and Sons, 1991

    Google Scholar 

  32. Cooper GL. The safety of fluoxetine — an update. Br J Psychiatry 1988; 153 Suppl. 3: 77–86

    Google Scholar 

  33. Ware MR, Stewart RB. Seizures associated with fluoxetine therapy [letter]. DICP Ann Pharmacother 1989; 23: 428

    CAS  Google Scholar 

  34. Weber JJ. Seizure activity associated with fluoxetine therapy. Clin Pharm 1989; 8(4): 296–8

    PubMed  CAS  Google Scholar 

  35. Riddle MA, Brown N, Dzubinski P. Fluoxetine overdose in an adolescent. J Am Acad Child Adolesc Psychiatry 1989; 28: 587–8

    Article  PubMed  CAS  Google Scholar 

  36. Krijzer F, Snelder M, Bradford D. Comparison of the (pro)convulsive properties of fluvoxamine and clovoxamine with eight other antidepressants in an animal model. Neuropsychobiology 1984; 12: 249–54

    Article  PubMed  CAS  Google Scholar 

  37. Harmant J, van Rijckevorsel-Harmant K, De Barsy TH, et al. Fluvoxamine: an antidepressant with low (or no) epileptogenic effect [letter]. Lancet 1990; 336: 386

    Article  PubMed  CAS  Google Scholar 

  38. Sedgwick EM, Cilasun J, Edwards JG. Paroxetine and the electroencephalogram. J Psychopharmacol 1987; 1: 31–4

    Article  PubMed  CAS  Google Scholar 

  39. Lader M, Melhuish A, Freka G, et al. The effect of Citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol 1986; 31: 183–90

    Article  PubMed  CAS  Google Scholar 

  40. Curran S. Effect of paroxetine on seizure length during electroconvulsive therapy. Acta Psychiatr Scand 1995; 92: 239–40

    Article  PubMed  CAS  Google Scholar 

  41. Curran S, Freeman CP. ECT and drugs. In: Freeman CP, editor. The ECT handbook: the second report of the Royal College of Psychiatrists Special Committee on ECT. London: Royal College of Psychiatrists, 1995: 49–57

    Google Scholar 

  42. Curran S, Lynch S. Scizure length during ECT. Br J Psychiatry 1996; 169: 525–6

    Article  PubMed  CAS  Google Scholar 

  43. Mishra PK, Kahle EH, Bettendorf AF, et al. Anticonvulsant effects of intracerebroventrically administered norepinephrine are potentiated in the presence of monoamine oxidase inhibition in severe seizure genetically epilepsy-prone rates (GEPR-9S). Life Sci 1993; 52(17): 1435–41

    Article  PubMed  CAS  Google Scholar 

  44. Medvedev AE, Gorkin VZ, Fedotova IB, et al. Increase of brain endogenous monoamine oxidase inhibitory activity (tribulin) in experimental audiogenic seizures in rats; evidence for a monoamine oxidase A inhibiting component of tribulin. Biochem Pharmacol 1992; 44(6): 1209–10

    Article  PubMed  CAS  Google Scholar 

  45. Schiwy W, Heath WR, Delini-Stula A. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor. Results of dose-finding trials in depressed patients. J Neural Transmission 1989; 28 Suppl.: 33–44

    CAS  Google Scholar 

  46. Mallakh RS, Lee RH. Seizures and transient cognitive deterioration as sequelae of acute lithium intoxication. Vet Human Toxicol 1987; 29(2): 143–5

    Google Scholar 

  47. Hansen HE, Amdisen A. Lithium intoxication. Q J Med 1978; 47: 123–44

    PubMed  CAS  Google Scholar 

  48. Mallakh RS, Lee RH. Seizures and transient cognitive deterioration as sequelae of acute lithium intoxication. Vet Hum Toxicol 1987; 29(2): 143–5

    PubMed  Google Scholar 

  49. Minabe Y, Emori K, Kurachi M. Effects of chronic lithium treatment on limbic seizure generation in the cat. Psychopharmacology 1988; 96(3): 391–4

    Article  PubMed  CAS  Google Scholar 

  50. Terry JB, Padzernik TL, Nelson SR. Effects of LiCl pretreatment on cholinomimetic-induced seizures and seizure-induced brain oedema in rats. Neurosci Lett 1990; 114(1): 123–7

    Article  PubMed  CAS  Google Scholar 

  51. Holden C. A guarded endorsement for shock therapy [letter]. Science 1985; 228: 1510

    Article  PubMed  CAS  Google Scholar 

  52. Rickels, Schweizer. Clinical overview of serotonin re-uptake inhibitors. J Clin Psychiatry 1990; 51 Suppl.: 9–12

    PubMed  Google Scholar 

  53. Duncan D, Taylor D. Which is the safest antidepressant to use in epilepsy? Psychiatric Bull 1995; 19: 355–7

    Article  Google Scholar 

  54. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 1997; 7 Suppl. 1: 37–47

    Article  Google Scholar 

  55. American Psychiatric Association. Controversies in depression. 150th Annual Meeting of the American Psychiatric Association; 1997 May 17–22: San Diego. Phase IV Communications: 1–4

    Google Scholar 

  56. Taylor D, Duncan D. Doses of carbamazepine and Valproate in bipolar affective disorder. Psychiatric Bull 1997; 21: 221–3

    Article  Google Scholar 

  57. Green AR. Changes in gamma aminobutyric acid biochemistry and seizure threshold. In: Malitz S, Sackeim HA, editors. Electroconvulsive therapy: clinical and basic research issues. New York: New York Academy of Sciences, 1986: 105–17

    Google Scholar 

  58. Post RM, Putnam F, Uhde TW, et al. Electroconvulsive therapy as an anticonvulsant: implications for its mechanism of action in affective illness. In: Malitz S, Sackeim HA, editors. Electroconvulsive therapy: clinical and basic research issues. New York: New York Academy of Sciences, 1986

    Google Scholar 

  59. Sackeim HA, Decina P, Prohovnik I, et al. Dosage, seizure threshold and antidepressant efficacy of electroconvulsive therapy. In: Malitz S, Sackeim HA, editors. Electroconvulsive therapy: clinical and basic research issues. New York: New York Academy of Sciences, 1986

    Google Scholar 

  60. Series HG. Drug treatment of depression in medically ill patients. J Psychosomatic Res 1992; 36(1): 1–16

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Psychiatry and Behavioural Sciences, University of Leeds, 15 Hyde Terrace, Leeds, LS2 9LT, England

    Stephen Curran

  2. St James’s University Hospital, Leeds, England

    Karel de Pauw

Authors
  1. Stephen Curran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karel de Pauw
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Curran, S., de Pauw, K. Selecting an Antidepressant for Use in a Patient with Epilepsy. Drug-Safety 18, 125–133 (1998). https://doi.org/10.2165/00002018-199818020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199818020-00004

Keywords

Search

Navigation